Scientific publications
Durable ventricular assist device in Spain (2007-2020). First report of the REGALAD registry
Manuel Gómez-Bueno 1 , Enrique Pérez de la Sota 2 , Alberto Forteza Gil 3 , Daniel Ortiz-Berbel 4 , Javier Castrodeza 5 , María Dolores García-Cosío Carmena 6 , Eduardo Barge-Caballero 7 , Diego Rangel Sousa 8 , Beatriz Díaz Molina 9 , Rebeca Manrique Antón 10 , Luis Almenar-Bonet 11 , Aitor Uribarri González 12 , Alfredo Barrio-Rodríguez 13 , María Ángeles Castel Lavilla 14 , Laura López-López 15 , David Dobarro Pérez 16 , Francisco Pastor Pérez 17 , Virginia Burgos-Palacios 18 , Jesús Álvarez-García 19 , José Manuel Garrido-Jiménez 20 , Óscar González-Fernández 21 , Pau Codina 22 , Amador López-Granados 23 , Andrés Grau-Sepulveda 24 , José González-Costello 25
Introduction and objectives
This report presents the clinical characteristics, outcomes and complications of all consecutive patients implanted with a long-term mechanical circulatory support device in Spain between 2007 and 2020.
Methods
Analysis of the Spanish registry of durable ventricular assist devices (REGALAD) including data form Spanish centers with a mechanical circulatory support program.
Results
During the study period, 263 ventricular assist devices were implanted in 22 hospitals. The implanted device was an isolated continuous-flow left ventricular assist device in 182 patients (69%), a pulsatile-flow device (58 isolated left ventricular and 21 biventricular) in 79 (30%), and a total artificial heart in 2 patients (1%). The strategy of the implant was as bridge to heart transplant in 78 patients (30%), bridge to candidacy in 110 (42%), bridge to recovery in 3 (1%) and destination therapy in 72 patients (27%). Overall survival at 6, 12 and 24 months was 79%, 74% and 69%, respectively, and was better in continuous-flow left ventricular assist devices (84%, 80%, and 75%). The main adverse events related to this therapy were infections (37% of patients), bleeding (35%), neurological (29%), and device malfunction (17%).
Conclusions
Durable ventricular assist devices have emerged in Spain in the last few years as a useful therapy for patients with advanced heart failure. As in other international registries, the current trend is to use continuous-flow intracorporeal left ventricular devices, which are associated with better results. Adverse events continue to be frequent and severe.
CITATION Rev Esp Cardiol (Engl Ed). 2022 Aug 30;S1885-5857(22)00213-4. doi: 10.1016/j.rec.2022.07.011
Our authors
